回盛生物(300871) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥242,303,822.17, a decrease of 11.72% compared to the same period last year[5] - The net profit attributable to shareholders was -¥1,020,585.75, reflecting a decline of 105.13% year-on-year[5] - The net cash flow from operating activities for the year-to-date was ¥57,060,213.12, down 22.19% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 691,386,248.86, an increase of 2.7% compared to CNY 671,478,771.75 in Q3 2022[22] - Net profit for Q3 2023 was CNY 14,877,358.41, a decrease of 43.8% from CNY 26,405,977.46 in Q3 2022[23] - The company reported a total profit of CNY 14,640,631.18 for Q3 2023, down from CNY 28,460,408.21 in the same quarter last year[23] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,911,146,466.59, a decrease of 2.61% from the end of the previous year[5] - The company's current assets decreased to CNY 1,207,394,074.06 from CNY 1,351,475,288.90, representing a reduction of about 10.6%[20] - Total liabilities as of Q3 2023 amounted to CNY 1,403,831,499.40, a slight decrease from CNY 1,447,682,082.36 at the end of Q3 2022[22] - The total liabilities decreased to CNY 1,207,394,074.06 from CNY 1,351,475,288.90, reflecting a decline of approximately 10.6%[20] - The total assets of the company as of Q3 2023 were CNY 2,911,146,466.59, down from CNY 2,989,114,303.25 in Q3 2022[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 12,649[13] - The largest shareholder, Wuhan Tongsheng Investment Co., Ltd., holds 49.91% of the shares, amounting to 82,800,000 shares[14] Cash Flow - The total cash inflow from operating activities for the period was CNY 744,551,814.05, an increase from CNY 728,233,144.34 in the previous period[25] - The net cash flow from operating activities decreased to CNY 57,060,213.12 from CNY 73,333,293.95 year-over-year[25] - Cash inflow from investment activities was CNY 753,246,841.44, significantly higher than CNY 373,890,015.74 in the previous period[26] - The net cash flow from investment activities was negative at CNY -175,201,771.95, improving from CNY -800,628,862.76 in the previous period[26] - Cash inflow from financing activities totaled CNY 234,000,720.00, compared to CNY 178,466,819.45 in the previous period[26] - The net cash flow from financing activities was CNY -41,053,633.66, an improvement from CNY -55,047,377.41 year-over-year[26] Expenses - The financial expenses increased by 47.49% to ¥13,643,213.72, primarily due to increased interest on convertible bonds[10] - Research and development expenses for Q3 2023 were CNY 31,206,491.12, compared to CNY 25,889,601.82 in Q3 2022, indicating a year-over-year increase of 20.5%[22] - The company paid CNY 103,186,997.03 to employees, an increase from CNY 78,923,768.74 in the previous period[25] - The company reported a cash outflow of CNY 505,647,676.19 for purchasing goods and services, slightly down from CNY 510,325,036.14 in the previous period[25] Other Financial Metrics - The weighted average return on equity was -0.07% for Q3 2023, a decrease of 1.34% year-on-year[5] - The investment income rose by 137.04% to ¥6,094,052.68, attributed to higher financial returns[10] - Deferred income increased to CNY 63,082,283.63 in Q3 2023 from CNY 48,888,649.20 in Q3 2022, representing a growth of 29.2%[22] - Earnings per share for Q3 2023 were CNY 0.09, down from CNY 0.16 in Q3 2022[23] - The total equity attributable to shareholders was CNY 1,507,314,967.19, down from CNY 1,541,432,220.89 year-over-year[22]